Poland · Delayed Price · Currency is PLN Read-Gene Statistics
Total Valuation
Read-Gene has a market cap or net worth of PLN 58.71 million. The enterprise value is 62.69 million.
| Market Cap | 58.71M |
| Enterprise Value | 62.69M |
Important Dates
The next confirmed earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Read-Gene has 11.79 million shares outstanding.
| Current Share Class | 1.49M |
| Shares Outstanding | 11.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.16% |
| Owned by Institutions (%) | n/a |
| Float | 1.27M |
Valuation Ratios
The trailing PE ratio is 30.12.
| PE Ratio | 30.12 |
| Forward PE | n/a |
| PS Ratio | 3.55 |
| PB Ratio | 19.10 |
| P/TBV Ratio | 19.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 598.51 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 32.16 |
| EV / Sales | 3.79 |
| EV / EBITDA | 23.49 |
| EV / EBIT | 28.38 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.79, with a Debt / Equity ratio of 2.66.
| Current Ratio | 19.79 |
| Quick Ratio | 19.62 |
| Debt / Equity | 2.66 |
| Debt / EBITDA | 3.07 |
| Debt / FCF | -22.26 |
| Interest Coverage | 6.68 |
Financial Efficiency
Return on equity (ROE) is 60.70% and return on invested capital (ROIC) is 31.54%.
| Return on Equity (ROE) | 60.70% |
| Return on Assets (ROA) | 9.86% |
| Return on Invested Capital (ROIC) | 31.54% |
| Return on Capital Employed (ROCE) | 16.73% |
| Weighted Average Cost of Capital (WACC) | 5.46% |
| Revenue Per Employee | 827,095 |
| Profits Per Employee | 97,477 |
| Employee Count | 20 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 21.72 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.26% in the last 52 weeks. The beta is 0.28, so Read-Gene's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +8.26% |
| 50-Day Moving Average | 5.19 |
| 200-Day Moving Average | 5.63 |
| Relative Strength Index (RSI) | 43.43 |
| Average Volume (20 Days) | 366 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Read-Gene had revenue of PLN 16.54 million and earned 1.95 million in profits.
| Revenue | 16.54M |
| Gross Profit | 15.67M |
| Operating Income | 2.21M |
| Pretax Income | 1.95M |
| Net Income | 1.95M |
| EBITDA | 2.67M |
| EBIT | 2.21M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 4.21 million in cash and 8.19 million in debt, with a net cash position of -3.98 million or -0.34 per share.
| Cash & Cash Equivalents | 4.21M |
| Total Debt | 8.19M |
| Net Cash | -3.98M |
| Net Cash Per Share | -0.34 |
| Equity (Book Value) | 3.07M |
| Book Value Per Share | n/a |
| Working Capital | 7.52M |
Cash Flow
In the last 12 months, operating cash flow was 98,100 and capital expenditures -465,792, giving a free cash flow of -367,692.
| Operating Cash Flow | 98,100 |
| Capital Expenditures | -465,792 |
| Depreciation & Amortization | 460,037 |
| Net Borrowing | n/a |
| Free Cash Flow | -367,692 |
| FCF Per Share | -0.03 |
Margins
Gross margin is 94.70%, with operating and profit margins of 13.35% and 11.79%.
| Gross Margin | 94.70% |
| Operating Margin | 13.35% |
| Pretax Margin | 11.79% |
| Profit Margin | 11.79% |
| EBITDA Margin | 16.13% |
| EBIT Margin | 13.35% |
| FCF Margin | n/a |
Dividends & Yields
Read-Gene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.32% |
| FCF Yield | -0.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Read-Gene has an Altman Z-Score of 5.73 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.73 |
| Piotroski F-Score | 6 |